John L. Marshall, MD

Articles

Dr Marshall on Updates in CRC Following the 2024 ASCO Annual Meeting

June 17th 2024

John L. Marshall, MD, discuss updates in colorectal cancer management at the 2024 ASCO Annual Meeting.

Trajectory of CRC Treatment Landscape

May 6th 2024

The panelists provide their final thoughts, exploring the prospective treatment landscape for patients with CRC.

MRD Testing in CRC: Gaps in our Understanding and Potential Advancements

May 6th 2024

The expert panel continues the discussion with thoughts on gaps in our understanding and application of MRD testing for colorectal cancer and a look to the future, highlighting potential advancements.

CIRCULATE-NORTH AMERICA and Barriers to Enrollment

April 29th 2024

Stacey Cohen, MD, discusses the rationale and study design of the phase 2/3 CIRCULATE-NORTH AMERICA study evaluating adjuvant chemotherapy selection based on MRD, and the panel discusses barriers to enrollment.

Recent Data from INTERCEPT and COSMOS-CRC-01 in Colorectal Cancer: Part 2

April 29th 2024

The panel continues its review of data presented on MRD testing in colorectal cancer from the INTERCEPT and COSMOS-CRC-01 studies.

Recent Data from INTERCEPT and COSMOS-CRC-01 in Colorectal Cancer

April 23rd 2024

The panel reviews recent data on MRD testing in colorectal cancer, highlighting the INTERCEPT and COSMOS-CRC-01 studies.

Patient Profile 2: A 35-Year-Old Man With Oligometastatic Colorectal Cancer

April 23rd 2024

Benjamin A. Weinberg, MD, presents the case of a 35-year-old man with oligometastatic disease, and the panel provides insights on treatment decisions.

Myths Surrounding Liquid Biopsy and ctDNA Testing for MRD

April 15th 2024

Pashtoon Murtaza Kasi, MD, MS, emphasizes key aspects of liquid biopsy and ctDNA testing in the MRD treatment landscape.

BESPOKE CRC: Study of ctDNA-Guided Therapy in Colorectal Cancer

April 15th 2024

Pashtoon Murtaza Kasi, MD, MS, reviews data from the BESPOKE CRC study, highlighting overall results and patient-reported outcomes.

Colorectal Cancer: Updates from the GALAXY Arm in CIRCULATE-Japan

April 9th 2024

Focusing on the GALAXY arm in the CIRCULATE-Japan study, experts on colorectal cancer discuss how recent data are informing the evolving treatment landscape.

Patient Profile: A 52-Year-Old Woman With Colorectal Cancer

April 1st 2024

John L. Marshall, MD, presents the case of a 52-year-old woman with mid-rectal carcinoma, and the panel offers its initial impressions.

Evolution of MRD Testing in Colorectal Cancer

April 1st 2024

The panel discusses how MRD testing has evolved as a clinical tool in colorectal cancer, highlighting the phase 2/3 COBRA study and its implications.

Practical Considerations in MRD Testing in CRC

March 25th 2024

Experts on colorectal cancer discuss practical considerations related to MRD testing, highlighting strategies to navigate potential challenges.

Colorectal Cancer: MRD Testing in the Community Setting

March 25th 2024

Pashtoon Murtaza Kasi, MD, MS, discusses MRD testing practices in the community oncology setting and provides recommendations on the integration of MRD testing into clinical practice.

Testing for MRD in Colorectal Cancer

March 18th 2024

Focusing on the adjuvant setting, the expert panel discusses the timing and frequency of MRD testing in patients with colorectal cancer.

MRD Testing Platforms in Colorectal Cancer

March 18th 2024

Colorectal cancer specialists discuss MRD testing platforms and how to choose among the available testing assays.

When is MRD Testing Performed in Colorectal Cancer Treatment?

March 11th 2024

Experts on colorectal cancer discuss the timing of testing for minimal residual disease in the treatment journey.

Treating Colorectal Cancer: Overview of MRD Testing and ctDNA

March 11th 2024

A panel medical oncologists provide an overview of circulating tumor DNA and its role in MRD (minimal residual disease) testing in the treatment of patients with colorectal cancer.

Dr Marshall on the FDA Approval of Fruquintinib in mCRC

November 9th 2023

John Lindsay Marshall, MD, discusses the significance of the FDA approval of fruquintinib (Fruzaqla) in patients with metastatic colorectal cancer.

Dr Marshall on Key Takeaways from the 2023 SOGO Annual Meeting in GI Cancer

May 8th 2023

John L. Marshall, MD, discusses the key takeaways from the 8th Annual School of Gastrointestinal Oncology® and remaining unmet needs for patients with metastatic colorectal cancer.